11-tert-butyloxycarbonylaminoundecanoic acid succinimidyl ester | 176242-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 11-tert-butyloxycarbonylaminoundecanoic acid succinimidyl ester
• 英文别名: Undecanoic acid, 11-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2,5-dioxo-1-pyrrolidinyl ester；(2,5-dioxopyrrolidin-1-yl) 11-[(2-methylpropan-2-yl)oxycarbonylamino]undecanoate
• CAS: 176242-02-7
• 化学式: C₂₀H₃₄N₂O₆
• 分子量: 398.5
• InChiKey: JLQGDKGMVLWFFC-UHFFFAOYSA-N

物化性质

• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  11-tert-butyloxycarbonylaminoundecanoic acid succinimidyl ester 在 碳酸氢钠 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 ((S)-4-(11-aminoundecanamido)cyclopent-1-en-1-yl)(butyl)phosphinic acid
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of ρ₁ GABA_C Receptors

  摘要：

  The rho(1) GABA(C) receptor is a ligand-gated chloride ion channel that shows promise as a therapeutic target for myopia, sleep disorders, memory and learning facilitation, and anxiety-related disorders. As such, there is a need for molecular probes to understand the role GABA(C) receptors play in physiological and pathological processes. To date, no labeled (either radioactive or fluorescent) GABA(C) selective ligand has been developed that can act as a marker for GABA(C) receptor visualization and localization studies. Herein, we report a series of fluorescent ligands containing different-sized linkers and fluorophores based around (S)-4-ACPBPA [(4-aminocyclopenten-1-yl)-butylphosphinic acid], a selective GABA(C) antagonist. One of these conjugates, (S)-4-ACPBPA-C5-BODIPY (13), displayed moderate potency (IC50 = 58.61 mu M) and selectivity (>100 times) for rho(1) over alpha(1)beta(2)gamma(2L) GABA(A) receptors. These conjugates are novel lead agents for the development of more potent and selective fluorescent probes for studying the localization and function of GABA(C) receptors in living cells.

  DOI：

  10.1021/ml300476v
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 11-tert-butyloxycarbonylaminoundecanoic acid succinimidyl ester
  参考文献：
  名称：

  [EN] ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES
  [FR] COMPOSITIONS ORGANIQUES POUR LETRAITEMENT DE PATHOLOGIES LIÉES À L'APOC3

  摘要：

  本公开涉及用于治疗与APOC3相关疾病的组合物和方法，例如：高甘油三酯血症（例如，V型高甘油三酯血症）、异常脂质代谢、异常胆固醇代谢、动脉粥样硬化、高脂血症、糖尿病，包括2型糖尿病、肥胖、心血管疾病和冠状动脉疾病等与异常代谢或其他障碍有关的疾病，使用对APOC3具有治疗作用的RNAi药剂的治疗有效量。

  公开号：

  WO2016011123A1

文献信息

• NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES
  申请人：BARNES David Weninger

  公开号：US20160030585A1

  公开（公告）日：2016-02-04

  The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R 1 , R 2 , R 3 , R 4 , Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种共轭物，其包括通过连接剂与脂肪酸连接的生物分子，其中所述的脂肪酸具有以下的化学式A1、A2或A3：其中，R1、R2、R3、R4、Ak、n、m和p在此定义。本发明还涉及一种制造GDF15共轭物等本发明共轭物的方法，以及其治疗用途，如治疗或预防代谢性疾病或疾病、2型糖尿病、肥胖症、胰腺炎、血脂异常、酒精性和非酒精性脂肪肝病/脂肪性肝炎和其他进行性肝脏疾病、胰岛素抵抗、高胰岛素血症、葡萄糖不耐受、高血糖、代谢综合征、高血压、心血管疾病、动脉粥样硬化、周围动脉疾病、中风、心力衰竭、冠心病、糖尿病并发症（包括但不限于慢性肾脏疾病）、神经病变、胃轻瘫和其他代谢性疾病。本发明还提供了药理活性剂的组合和制药组合物。
• Organic compositions to treat APOC3-related diseases
  申请人：Arrowhead Pharmaceuticals, Inc.

  公开号：US10240153B2

  公开（公告）日：2019-03-26

  The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.

  本公开涉及治疗 APOC3 相关疾病的组合物和方法，这些疾病包括：高甘油三酯血症（如 V 型高甘油三酯血症）、脂质代谢异常、胆固醇代谢异常、动脉粥样硬化、高脂血症、糖尿病（包括 2 型糖尿病）、肥胖、心血管疾病和冠状动脉疾病，以及其他与代谢异常或其他有关的疾病。
• Fatty acids and their use in conjugation to biomolecules
  申请人：NOVARTIS AG

  公开号：US10786576B2

  公开（公告）日：2020-09-29

  The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种共轭物，该共轭物包括通过连接剂与脂肪酸连接的生物大分子，其中脂肪酸具有下式 A1、A2 或 A3： 其中 R1、R2、R3、R4、Ak、n、m 和 p 在本文中定义。本发明还涉及一种制造本发明共轭物（如 GDF15 共轭物）的方法及其治疗用途，如治疗或预防代谢紊乱或疾病、2 型糖尿病、肥胖症、胰腺炎、血脂异常、酒精性和非酒精性脂肪肝/骨转移性肝炎及其他进行性肝病、胰岛素抵抗、高胰岛素血症、葡萄糖不耐受、高血糖、代谢综合征、高血压、心血管疾病、动脉粥样硬化、外周动脉疾病、中风、心力衰竭、冠心病、糖尿病并发症（包括但不限于慢性肾病）、神经病变、胃痉挛和其他代谢紊乱。本发明进一步提供了药理活性制剂和药物组合物的组合。
• [EN] FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES<br/>[FR] ACIDES GRAS ET LEUR UTILISATION DANS LA CONJUGAISON DE BIOMOLÉCULES
  申请人：NOVARTIS AG

  公开号：WO2015200078A8

  公开（公告）日：2016-04-14
• RNAI COMPOSITIONS TO TREAT APOC3-RELATED DISEASES
  申请人：Arrowhead Pharmaceuticals, Inc.

  公开号：EP3169784B1

  公开（公告）日：2020-06-10